全文获取类型
收费全文 | 319144篇 |
免费 | 42766篇 |
国内免费 | 2924篇 |
专业分类
耳鼻咽喉 | 7377篇 |
儿科学 | 9840篇 |
妇产科学 | 5720篇 |
基础医学 | 26021篇 |
口腔科学 | 4965篇 |
临床医学 | 42796篇 |
内科学 | 82491篇 |
皮肤病学 | 9951篇 |
神经病学 | 31947篇 |
特种医学 | 12245篇 |
外国民族医学 | 13篇 |
外科学 | 65379篇 |
综合类 | 2570篇 |
现状与发展 | 75篇 |
一般理论 | 202篇 |
预防医学 | 19891篇 |
眼科学 | 8013篇 |
药学 | 12329篇 |
中国医学 | 211篇 |
肿瘤学 | 22798篇 |
出版年
2023年 | 5253篇 |
2022年 | 2135篇 |
2021年 | 5791篇 |
2020年 | 7535篇 |
2019年 | 4900篇 |
2018年 | 10425篇 |
2017年 | 9463篇 |
2016年 | 10874篇 |
2015年 | 11445篇 |
2014年 | 19944篇 |
2013年 | 22736篇 |
2012年 | 16496篇 |
2011年 | 17309篇 |
2010年 | 16643篇 |
2009年 | 19801篇 |
2008年 | 16943篇 |
2007年 | 16040篇 |
2006年 | 17875篇 |
2005年 | 15628篇 |
2004年 | 14342篇 |
2003年 | 12841篇 |
2002年 | 12528篇 |
2001年 | 5082篇 |
2000年 | 3969篇 |
1999年 | 4611篇 |
1998年 | 5734篇 |
1997年 | 5249篇 |
1996年 | 4839篇 |
1995年 | 4571篇 |
1994年 | 3233篇 |
1993年 | 2838篇 |
1992年 | 2338篇 |
1991年 | 2268篇 |
1990年 | 1829篇 |
1989年 | 1931篇 |
1988年 | 1790篇 |
1987年 | 1530篇 |
1986年 | 1664篇 |
1985年 | 1593篇 |
1984年 | 1744篇 |
1983年 | 1654篇 |
1982年 | 2113篇 |
1981年 | 1885篇 |
1980年 | 1750篇 |
1979年 | 1067篇 |
1978年 | 1210篇 |
1977年 | 1173篇 |
1976年 | 934篇 |
1975年 | 823篇 |
1974年 | 806篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
81.
82.
Stefan Scholz Florian Koerber Kinga Meszaros Rosa Maya Fassbender Bernhard Ultsch Robert R. Welte Wolfgang Greiner 《Vaccine》2019,37(12):1692-1701
Introduction
Invasive meningococcal disease (IMD) is a severe disease mainly affecting infants and young children. The most common serogroup causing IMD in Germany is the serogroup type B Neisseria meningitidis (MenB). The aim of the present study is to estimate the economic burden of MenB-related IMD in Germany.Method
A bottom-up, model-based costing approach has been used to calculate the diagnose- and age-specific yearly lifetime costs of a hypothetical cohort of MenB-related IMD cases. Direct costs contain the treatment cost for the acute phase of the disease, long-term sequelae, costs for rehabilitation, and public health response. Indirect costs are calculated for the human-capital approach and the friction-cost approach considering productivity losses of patients or parents for the acute phase and long-term sequelae. Publicly available databases from the Federal Statistical Office, the SOEP panel data set, literature, and expert opinion were used as data sources. All future costs beyond the reference year of 2015 were discounted at 3%.Results
The total costs for the hypothetical cohort (343 patients) from a societal perspective are €19.6 million (€57,100/IMD case) using the friction-cost approach and €58.8 million (€171,000/IMD case) using the human-capital approach. Direct costs amount to €18.6 million or €54,300 €/case. Sequelae are responsible for 81% of the direct costs/case.Discussion
The elevated costs/MenB-related IMD case reflect the severity of the disease. The total costs are sensitive to the productivity-loss estimation approach applied. MenB is an uncommon but severe disease; The costs/case reflect the severity of the disease and is within the same magnitude as for human papilloma virus infections. The available literature on sequelae is due to the uncommonness limited and heterogeneous. 相似文献83.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
84.
85.
86.
87.
88.
89.
90.